Pre-Conference Day

Defining Immune Resetting: Translational Approaches to Profiling B-Cells to Understand the Depth of Depletion

Join this workshop to discuss how we measure the immune reset and to what depth must we deplete B-Cells:

• Clarifying the constitution of a true ‘immune reset’ following B-cell depletion therapy vs transient immunosuppression
• Discussing the restoration of the stable self-tolerant immune system
• Understanding optimal depletion targets to understand which populations must be depleted and to what extent to achieve a sustainable therapeutic effect
• Reflecting on the necessary therapeutic strategies needed to target long-lived plasma cells within the bone marrow
• Advancing B-cell profiling techniques such as single-cell RNA sequencing, flow, and mass cytometry, and adaptive immune receptor repertoire sequencing
• Discussing the effective definition of B-cell depletion through cellular and molecular biomarkers that correlate with depletion depth and sustained immune reset

Advancing Diagnostics & Biomarkers to Definitively Characterize the B-Cell Repertoire & Success of Immune Resetting Therapeutics in a Clinical Setting

Join this workshop to explore how immune resetting is being measured in the clinic:

• Highlighting the disconnect between B-cell levels in peripheral blood and their persistence in the lymph nodes following conventional antibody therapies
• Discussing the necessity of lymph node biopsies as a direct, ex vivo method to accurately quantify the depth of depletion to address the disruption of the follicular pathway in the lymph nodes to provide a measure of therapeutic effects
• Comparing the tissue outcomes across different therapeutic modalities linking deep lymphoid tissue depletion to the potential for sustained, long-term remission
• Effectively analyzing the B-cell repertoire to gain insights into effectiveness of the treatment after resetting the immune system
• Utilizing B-cell receptor gene sequencing to precisely track and confirm the deep and sustained elimination of these initial pathogenic B-cells following immuneresetting therapy
• Ensuring newly generated B-cells are free of the original pathogenic B-cells as molecular evidence for the restoration of self-tolerance
• Establishing molecular signatures that predict long-term remission